Confirmed Control Closed Transaction verified BiopharmaceuticalsEye Care TherapeuticsOphthalmic Pharmaceuticals
Oyster Point Pharma acquired by Viatris
Viatris acquired Oyster Point Pharma, an ophthalmic pharmaceuticals brand on Nov 7, 2022. Financial terms were not publicly disclosed. Public sources confirm the deal; valuation inputs may include estimates where transaction materials do not disclose the full economics.
Transaction summary
- Target
- Oyster Point Pharma
- Acquirer
- Viatris
- Seller
- -
- Announced
- 2022-11-07
- Geography
- -
- Tags
- BiopharmaceuticalsEye Care TherapeuticsOphthalmic Pharmaceuticals
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- -
- First added
- 2026-06-19
- Latest update
- 2026-06-19
Value and multiples
Price / value
Undisclosed
Transaction value
Basis: FundComb estimate
EV / revenue
-
Period not stated
Basis: FundComb estimate
EV / EBITDA
20.7x
EBITDA basis not stated
Basis: FundComb estimate
Basis
- Financial terms were not disclosed in the public sources reviewed.
- EV / EBITDA is shown as 20.7x based on the available comp inputs.
- EBITDA and multiple inputs are not fully disclosed in public transaction materials reviewed; treat the multiple as an estimate.
- EBITDA basis was not stated in the source material.
Source summary
No public source summary has been published for this transaction yet.